The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index; none of the 34 sources its claims cite is checked for support yet.
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Open accessAbstract
BACKGROUND: Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that is selective for both EGFR-TKI sensitizing and T790M resistance mutations in patients with non-small-cell lung cancer. The efficacy of osimertinib as compared with platinum-based therapy plus pemetrexed in such patients is unknown. METHODS: In this randomized, international, open-label, phase 3 trial, we assigned 419 patients with T790M-positive advanced non-small-cell lung cancer, who had disease progression after first-line EGFR-TKI therapy, in a 2:1 ratio to receive either oral osimertinib (at a dose of 80 mg once daily) or intravenous pemetrexed (500 mg per square meter of body-surface area) plus either carboplatin (target area under the curve, 5 [AUC5]) or cisplatin (75 mg per square meter) every 3 weeks for up to six cycles; maintenance pemetrexed was allowed. In all the patients, disease had progressed during receipt of first-line EGFR-TKI therapy. The primary end point was investigator-assessed progression-free survival. RESULTS: The median duration of progression-free survival was significantly longer with osimertinib than with platinum therapy plus pemetrexed (10.1 months vs. 4.4 months; hazard ratio; 0.30; 95% confidence interval [CI], 0.23 to 0.41; P<0.001). The objective response rate was significantly better with osimertinib (71%; 95% CI, 65 to 76) than with platinum therapy plus pemetrexed (31%; 95% CI, 24 to 40) (odds ratio for objective response, 5.39; 95% CI, 3.47 to 8.48; P<0.001). Among 144 patients with metastases to the central nervous system (CNS), the median duration of progression-free survival was longer among patients receiving osimertinib than among those receiving platinum therapy plus pemetrexed (8.5 months vs. 4.2 months; hazard ratio, 0.32; 95% CI, 0.21 to 0.49). The proportion of patients with adverse events of grade 3 or higher was lower with osimertinib (23%) than with platinum therapy plus pemetrexed (47%). CONCLUSIONS: Osimertinib had significantly greater efficacy than platinum therapy plus pemetrexed in patients with T790M-positive advanced non-small-cell lung cancer (including those with CNS metastases) in whom disease had progressed during first-line EGFR-TKI therapy. (Funded by AstraZeneca; AURA3 ClinicalTrials.gov number, NCT02151981 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 34 cited sources checked · 0 supported · 0 flagged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“On the basis of investigator assessment, the median response duration was 9.7 months (95% CI, 8.3 to 11.6) in the osimertinib group and 4.1 months (95% CI, 3.0 to 5.6) in the platinum–pemetrexed group.”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > RESULTS > EFFICACY
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The objective response rate was significantly better with osimertinib (71%; 95% CI, 65 to 76) than with platinum therapy plus pemetrexed (31%; 95% CI, 24 to 40) (odds ratio for objective response, 5.39; 95% CI, 3.47 to 8.48; P<0.001).”
- Also stated in: § EFFICACY · plain
“The response rate was significantly better in the osimertinib group (71%; 95% CI, 65 to 76) than in the platinum–pemetrexed group (31%; 95% CI, 24 to 40) (odds ratio, 5.39; 95% CI, 3.47 to 8.48; P<0.001) (Table 2).”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > Abstract > RESULTS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § EFFICACY · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Improvement in outcomes with osimertinib over platinum–pemetrexed in the tumor and plasma ctDNA T790M-positive subgroup was similar to that in the intention-to-treat population.”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > DISCUSSION
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The most commonly reported adverse events in the platinum–pemetrexed group were nausea (in 67 patients [49%]), decreased appetite (in 49 [36%]), constipation (in 47 [35%]), and anemia (in 41 [30%]).”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > RESULTS > SAFETY AND ADVERSE EVENTS
Strength:plain· not yet calibratedn = 67Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The proportion of patients with adverse events of grade 3 or higher was lower with osimertinib (23%) than with platinum therapy plus pemetrexed (47%).”
- Also stated in: § SAFETY AND ADVERSE EVENTS · plain
“Fewer patients reported adverse events of grade 3 or more in the osimertinib group than in the platinum–pemetrexed group (63 [23%] vs. 64 [47%]).”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > Abstract > RESULTS
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § SAFETY AND ADVERSE EVENTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In a mixed model for repeated-measures analysis, patient-reported outcomes were better in the osimertinib group than in the platinum–pemetrexed group across five prespecified symptoms during the overall period from randomization until 6 months (Table S4 in the Supplementary Appendix).”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > RESULTS > EFFICACY
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A similar finding was observed in the subgroup of patients with T790M-positive status on both tumor and plasma analyses (89 of 116 patients [77%] vs. 22 of 56 patients [39%]; odds ratio, 4.96; 95% CI, 2.49 to 10.15; P<0.001).”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > RESULTS > EFFICACY
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Osimertinib was associated with a lower rate of adverse events leading to permanent discontinuation than was platinum–pemetrexed (in 19 patients [7%] and 14 patients [10%], respectively).”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > RESULTS > SAFETY AND ADVERSE EVENTS
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median duration of progression-free survival among patients with tumor and plasma T790M-positive status was 8.2 months in the osimertinib group versus 4.2 months in the platinum–pemetrexed group (hazard ratio, 0.42; 95% CI, 0.29 to 0.61) (Fig. 1C).”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > RESULTS > EFFICACY
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Fatal adverse events were reported in 4 patients in the osimertinib group (respiratory failure in 2, pneumonitis in 1, and ischemic stroke in 1). One fatal adverse event of hypovolemic shock was reported in the platinum–pemetrexed group.”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > RESULTS > SAFETY AND ADVERSE EVENTS
Strength:plain· not yet calibratedn = 4Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes
- It may state two separate claims as one. 12
- Probably not a substantial claim. 7
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A prolongation in the QT interval was recorded in 10 patients (4%) in the osimertinib group and 1 patient (1%) in the platinum–pemetrexed group, with all events of grade 1 or 2 in severity except for one grade 3 event in the osimertinib group.”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > RESULTS > SAFETY AND ADVERSE EVENTS
Strength:plain· not yet calibratedn = 10Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The hazard ratio for progression-free survival favored osimertinib across all predefined subgroups that were analyzed (hazard ratio, <0.50 for each subgroup) (Fig. 2), including patients with CNS metastases (median duration of progression-free survival, 8.5 months vs. 4.2 months; hazard ratio, 0.32; 95% CI, 0.21 to 0.49) (Fig. 1B).”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > RESULTS > EFFICACY
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The duration of progression-free survival according to blinded independent central review was consistent with the investigator-assessed durations, with a median of 11.0 months versus 4.2 months (adjusted hazard ratio, 0.28; 95% CI, 0.20 to 0.38; P<0.001).”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > RESULTS > EFFICACY
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Interstitial lung disease–like adverse events were reported in 10 patients (4%) in the osimertinib group (nine events of grade 1 or 2 in severity and one death) and in 1 patient (1%) in the platinum–pemetrexed group (one grade 3 event).”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > RESULTS > SAFETY AND ADVERSE EVENTS
Strength:plain· not yet calibratedn = 10Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All the patients who underwent randomization were included in the intention-to-treat population, which was used for all efficacy analyses.”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > METHODS > STATISTICAL ANALYSIS
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Overall, adverse events tended to be more severe in the platinum–pemetrexed group, despite the longer treatment duration with osimertinib.”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > DISCUSSION
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The safety analysis included all the patients in the intention-to-treat population who had received at least one dose of a trial drug and for whom data were available after the administration of the drug.”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > METHODS > STATISTICAL ANALYSIS
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“The presence of the T790M variant reduces binding of first-generation or second-generation EGFR-TKIs to the ATP-binding pocket of EGFR, thereby reducing EGFR-TKI–mediated inhibition of downstream signaling and potentially leading to disease progression.17–19”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [17] Yun CH, Mengwasser KE, Toms AV, The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 2008; 105: 2070– 5. 18227510 PMC2538882 source
- Not checked yetcites [18] Sos ML, Rode HB, Heynck S, Chemogenomic profiling provides insights into the limited activity of irreversible EGFR inhibitors in tumor cells expressing the T790M EGFR resistance mutation. Cancer Res 2010; 70: 868– 74. 20103621 source
- Not checked yetcites [19] Cross DA, Ashton SE, Ghiorghiu S, AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014; 4: 1046– 61. 24893891 PMC4315625 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“These findings were confirmed in a pooled analysis of two subsequent phase 2 studies of osimertinib (at a dose of 80 mg once daily) in 411 patients with T790M-positive non–small-cell lung cancer, in which the response rate was 66% on blinded independent central review and the median duration of progression-free survival was 11.0 months.23”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [23] Yang J, Ramalingam SS, Jänne PA, Cantarini M, Mitsudomi T. LBA2_PR: Osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) results. J Thorac Oncol 2016; 11: Suppl: S152– S153. source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The trial was conducted in accordance with the provisions of the Declaration of Helsinki, Good Clinical Practice guidelines (as defined by the International Conference on Harmonisation), applicable regulatory requirements, and the policy on bioethics and human biologic samples of the trial sponsor, AstraZeneca.”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > METHODS > TRIAL OVERSIGHT
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“We determined that 221 events of progression or death would provide a power of 80% to reject the null hypothesis of no significant difference in the duration of progression-free survival between the two treatment groups, assuming a treatment effect hazard ratio of 0.67 with a P value of 0.05 indicating two-sided statistical significance.”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > METHODS > STATISTICAL ANALYSIS
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Osimertinib is an oral, irreversible EGFR-TKI that is selective for both EGFR and T790M resistance mutations with activity in the central nervous system (CNS).19–21”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [19] Cross DA, Ashton SE, Ghiorghiu S, AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014; 4: 1046– 61. 24893891 PMC4315625 source
- Not checked yetcites [20] Ballard P, Yates JW, Yang Z, Pre-clinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res 2016; 22: 5130– 40. 27435396 source
- Not checked yetcites [21] Yang JC-H, Kim D-W, Kim S-W, Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): updated results from BLOOM, a phase I study. J Clin Oncol 2016; 34: Suppl: 9002 abstract. source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Among patients with advanced non–small-cell lung cancer with a mutant epidermal growth factor receptor (EGFR), EGFR tyrosine kinase inhibitors (TKIs) are the standard first-line therapy.1–4”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [1] Masters GA, Temin S, Azzoli CG, Systemic therapy for Stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline update. J Clin Oncol 2015; 33: 3488– 515. 26324367 PMC5019421 source
- Not checked yetcites [2] Novello S, Barlesi F, Califano R, Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27: Suppl 5: v1– v27. 27664245 source
- Not checked yetcites [3] Tan DS, Yom SS, Tsao MS, The International Association for the Study of Lung Cancer consensus statement on optimizing management of EGFR mutation-positive non-small cell lung cancer: status in 2016. J Thorac Oncol 2016; 11: 946– 63. 27229180 source
- Not checked yetcites [4] National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: NSCLC (version 3.2017). 2016 (http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf). 28188192 source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“A sensitivity analysis of progression-free survival by blinded independent central review was conducted.”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > METHODS > TRIAL END POINTS
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Patients were stratified according to Asian or non-Asian race and were randomly assigned in a 2:1 ratio to receive oral osimertinib (at a dose of 80 mg once daily) or intravenous pemetrexed (500 mg per square meter of body-surface area) plus either carboplatin (target area under the curve 5 [AUC5]) or cisplatin (75 mg per square meter) every 3 weeks for up to six cycles.”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > METHODS > TRIAL DESIGN AND TREATMENT
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“In AURA3, the safety profile for osimertinib was consistent with that reported previously and differed from that in the platinum–pemetrexed group.23”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > DISCUSSION
What the sources say
- Not checked yetcites [23] Yang J, Ramalingam SS, Jänne PA, Cantarini M, Mitsudomi T. LBA2_PR: Osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) results. J Thorac Oncol 2016; 11: Suppl: S152– S153. source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“In the phase 1 component of AURA, a phase 1/2 trial (ClinicalTrials.gov number, ), the objective response rate for osimertinib in patients with T790M-positive non–small-cell lung cancer was 61%; the median duration of progression-free survival was 9.6 months.22”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [22] Jänne PA, Yang JC-H, Kim D-W, AZD9291 in EGFR inhibitor–resistant non–small-cell lung cancer. N Engl J Med 2015; 372: 1689– 99. 25923549
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper relies on this without support.
Platinum-pemetrexed was the standard of care for patients with T790M-positive advanced NSCLC after first-line EGFR-TKI at the time of trial initiation.
“Chemotherapy was the standard control at the time of trial initiation.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In T790M-positive tumors, following progression after first- or second-generation EGFR TKIs, second-line osimertinib has demonstrated significant efficacy compared with chemotherapy (median PFS: 10.1 vs 4.4 months; HR, 0.30 (95% CI, 0.23‒0.40), P < 0.001).”
From Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings (2020) · cites this paper as [48]
Experimental — accuracy not yet measuredIn the citing paper
“In addition to being used alone, osimertinib is also being studied in combination with other targeted therapies for NSCLC, such as inhibitors of the Met, Bcl-2, and MAPK pathways.138–140”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [140]
In the citing paper
“Even more variable are duration of response to targeted therapy, progression-free survival and overall survival16–26, 28–32, 35.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [21]
In the citing paper
“Across clinical trials of first-line targeted therapy for oncogene-addicted subgroups of NSCLC, rates of objective response [G] typically range between 50% and 83% and complete responses [G] are rare; in addition, some patients exhibit de novo resistance16–26, 28–32, 35.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [21]
In the citing paper
“In a randomized phase III trial[3], osimertinib significantly improved both progression-free survival (PFS) and objective response rate (ORR) when compared to platinum-pemetrexed chemotherapy for T790M-positive non-small cell lung cancer (NSCLC) after progression on 1st or 2nd generation EGFR-TKIs.”
From Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC (2018) · cites this paper as [3]
In the citing paper
“In the AURA3 phase III trial, osimertinib demonstrated signi fi cantly higher ef fi cacy than platinum-based chemotherapy in patients with T790M-positive NSCLC. 14”
From Osimertinib for Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09) (2020) · cites this paper as [14]
In the citing paper
“Osimertinib was granted accelerated approval by the FDA in 2015 as a second-line treatment for NSCLC, and was approved as a first-line treatment for metastatic NSCLC in 2018 (ref.49).”
From Advances in covalent drug discovery (2022) · cites this paper as [49]
Citations
Cites
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Self-citationGefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090
Zhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081
Self-citationEGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Sequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228
Self-citationNovello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631
Yu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., Kris, M. G., Miller, V. A., Ladanyi, M., & Riely, G. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2246 · Cited by 2,454
Flagged first, then by citations
Research works printed but not linked: 1
- Soria J, 2015, J Thorac Oncol, 10, S207
Cited by
Sorted by citations
Items 301–400 of 1,003
Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies
Ou, X., Gao, G., Habaz, I. A., & Wang, Y. (2024) · MedComm · doi:10.1002/mco2.694 · Cited by 104
Nanjo, S., Hata, A., Okuda, C., Kaji, R., Okada, H., Tamura, D., Irie, K., Okada, H., Fukushima, S., & Katakami, N. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.394 · Cited by 94
Passiglia, F., Rizzo, S., Maïo, M. D., Galvano, A., Badalamenti, G., Listì, A., Gulotta, L., Castiglia, M., Fulfaro, F., Bazan, V., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-30780-4 · Cited by 93
Jiang, T., Wang, P., Zhang, J., Zhao, Y., Zhou, J., Fan, Y., Shu, Y., Liu, X., Zhang, H., He, J., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00751-9 · Cited by 95
Cardiac Safety of Osimertinib: A Review of Data
Ewer, M. S., Tekumalla, S. H., Walding, A., & Atuah, K. N. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01171 · Cited by 91
Corvaja, C., Passaro, A., Attili, I., Aliaga, P. T., Spitaleri, G., Signore, E. D., & de Marinis, F. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102824 · Cited by 94
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
Fang, W., Wu, L., Meng, X., Yao, Y., Zuo, W., Yao, W., Xie, Y., Zhang, Y., Cui, J., Zhang, Y., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2512071 · Cited by 91
Genomics and the History of Precision Oncology
Doroshow, D. B., & Doroshow, J. H. (2019) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.08.003 · Cited by 93
Yang, C., Liao, W., Ho, C., Chen, K., Tsai, T.-H., Hsu, C., Su, K., Chang, Y., Wu, C., Hsu, C., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.10.019 · Cited by 90
PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice
Eguren‐Santamaría, I., Sanmamed, M. F., Goldberg, S. B., Kluger, H. M., Idoate, M. A., Lu, B. Y., Corral, J., Schalper, K. A., Herbst, R. S., & Bazo, I. G. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0798 · Cited by 90
Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma
Rybarczyk-Kasiuchnicz, A., Ramlau, R., & Stencel, K. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020593 · Cited by 94
Role of Small Molecule Targeted Compounds in Cancer: Progress, Opportunities, and Challenges
Sun, G., Rong, D., Li, Z., Sun, G., Wu, F., Li, X., Cao, H., Cheng, Y., Tang, W., & Sun, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.694363 · Cited by 89
Cardiac Adverse Events in EGFR-Mutated Non-Small Cell Lung Cancer Treated With Osimertinib
Kunimasa, K., Kamada, R., Oka, T., Oboshi, M., Kimura, M., Inoue, T., Tamiya, M., Nishikawa, T., Yasui, T., Shioyama, W., et al. (2020) · JACC CardioOncology · doi:10.1016/j.jaccao.2020.02.003 · Cited by 87
Management of Brain Metastases in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer
Kelly, W., Shah, N. J., & Subramaniam, D. S. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00208 · Cited by 86
Lim, S. M., Fujino, T., Kim, C., Lee, G., Lee, Y.-H., Kim, D., Ahn, J. S., Mitsudomi, T., Jin, T. J., & Lee, S.-Y. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3901 · Cited by 90
Namba, K., Shien, K., Takahashi, Y., Torigoe, H., Sato, H., Yoshioka, T., Takeda, T., Kurihara, E., Ogoshi, Y., Yamamoto, H., et al. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0628 · Cited by 86
Hochmair, M. J., Morabito, A., Hao, D., Yang, C.-T., Soo, R. A., Yang, J. C.-H., Gucalp, R., Halmos, B., Wang, L., Märten, A., et al. (2019) · Future Oncology · doi:10.2217/fon-2019-0346 · Cited by 85
Jin, Y. H., Xu, Z., Yan, H., He, Q., Yang, X., & Luo, P. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00891 · Cited by 88
Haikala, H. M., Lopez, T., Köhler, J., Eser, P. O., Xu, M., Zeng, Q., Teceno, T. J., Ngo, K., Zhao, Y., Ivanova, E. V., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-2426 · Cited by 85
The oligometastatic spectrum in the era of improved detection and modern systemic therapy
Katipally, R. R., Pitroda, S. P., Juloori, A., Chmura, S. J., & Weichselbaum, R. R. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00655-9 · Cited by 87
Advanced-Stage Non–Small Cell Lung Cancer: Advances in Thoracic Oncology 2018
Remón, J., Ahn, M., Girard, N., Johnson, M. L., Kim, D., Lopes, G. D. L., Jr., Pillai, R. N., Solomon, B., Villacampa, G. J., & Zhou, Q. H. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.03.022 · Cited by 84
Self-citationMasood, A., Kancha, R. K., & Subramanian, J. (2019) · Seminars in Oncology · doi:10.1053/j.seminoncol.2019.08.004 · Cited by 86
Zhai, X., Ward, R. A., Doig, P. C., & Argyrou, A. (2020) · Biochemistry · doi:10.1021/acs.biochem.0c00104 · Cited by 84
Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Non−Small Cell Lung Cancer
Dong, S., Wang, Z., Zhang, J., Yan, B., Zhang, C., Gao, X., Sun, H., Li, Y.-S., Yan, H., Tu, H.-Y., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.1779 · Cited by 84
Self-citationMonica, S. L., Cretella, D., Bonelli, M. A., Fumarola, C., Cavazzoni, A., Digiacomo, G., Flammini, L., Barocelli, E., Minari, R., Naldi, N., et al. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0653-7 · Cited by 82
Shaurova, T., Zhang, L., Goodrich, D. W., & Hershberger, P. A. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00281 · Cited by 82
Tackling Osimertinib Resistance in EGFR-Mutant Non–Small Cell Lung Cancer
Blaquier, J. B., Ortiz‐Cuaran, S., Ricciuti, B., Mezquita, L., Cardona, A. F., & Recondo, G. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1912 · Cited by 82
Wu, B. Y., Gu, X., & Zhang, Q. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.10.012 · Cited by 83
Enabling Precision Oncology Through Precision Diagnostics
Brown, N. A., & Elenitoba‐Johnson, K. S. J. (2020) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-012735 · Cited by 84
Molecular therapeutic targets in non-small cell lung cancer
Sankar, K. N., Gadgeel, S. M., & Qin, A. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1787156 · Cited by 85
Targeted Inhibitors of EGFR: Structure, Biology, Biomarkers, and Clinical Applications
Shaban, N., Kamashev, D., Emelianova, A., & Buzdin, A. A. (2023) · Cells · doi:10.3390/cells13010047 · Cited by 88
Tanaka, K., Nosaki, K., Otsubo, K., Azuma, K., Sakata, S., Ouchi, H., Morinaga, R., Wataya, H., Fujii, A., Nakagaki, N., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19243 · Cited by 84
Using Genome Sequence to Enable the Design of Medicines and Chemical Probes
Angelbello, A. J., Chen, J. L., Childs‐Disney, J. L., Zhang, P., Wang, Z.-F., & Disney, M. D. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00504 · Cited by 81
Rebuzzi, S. E., Alfieri, R. R., Monica, S. L., Minari, R., Petronini, P. G., & Tiseo, M. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.102820 · Cited by 80
Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer
Cui, W., Franchini, F., Alexander, M., Officer, A., Wong, H., IJzerman, M. J., Desai, J., & Solomon, B. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.06.030 · Cited by 80
Ahn, M., Cho, B. C., Ou, X., Walding, A., Dymond, A. W., Ren, S., Cantarini, M., & Janne, P. A. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.01.012 · Cited by 80
Self-citationChallenges in the Use of Targeted Therapies in Non–Small Cell Lung Cancer
Rivera‐Concepción, J., Uprety, D., & Adjei, A. A. (2022) · Cancer Research and Treatment · doi:10.4143/crt.2022.078 · Cited by 84
Herbst, R. S., John, T., Grohé, C., Goldman, J. W., Kato, T., Лактионов, К. К., Bonanno, L., Tiseo, M., Majem, M., Dómine, M., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03577-y · Cited by 80
Self-citationKnebel, F. H., Bettoni, F., Shimada, A. K., Cruz, M., Alessi, J. V., Negrao, M. V., Reis, L. F. L., Katz, A., & Camargo, A. A. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.04.004 · Cited by 79
Bylicki, O., Paleiron, N., Margery, J., Guisier, F., Vergnenégre, A., Robinet, G., Auliac, J. B., Gervais, R., & CHOUAID, C. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0510-9 · Cited by 82
Re, M. D., Crucitta, S., Gianfilippo, G., Passaro, A., Petrini, I., Restante, G., Michelucci, A., Fogli, S., de Marinis, F., Porta, C., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20163951 · Cited by 84
Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?
Bonanno, L., Maso, A. D., Pavan, A., Zulato, E., Calvetti, L., Pasello, G., Guarneri, V., Conte, P., & Indraccolo, S. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01777-8 · Cited by 81
Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment
Remón, J., & Besse, B. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00088 · Cited by 80
Ng, T. L., Liu, Y., Dimou, A., Patil, T., Aisner, D. L., Dong, Z., Jiang, T., Su, C., Wu, C., Ren, S., et al. (2018) · Cancer · doi:10.1002/cncr.31871 · Cited by 78
Stone, J., Perue, R. K., Abbasi, M. A., & Akhtari, M. (2021) · JCO Oncology Practice · doi:10.1200/op.20.00924 · Cited by 78
Okamoto, I., Morita, S., Tashiro, N., Imamura, F., Inoue, A., Seto, T., Yamamoto, N., Ohe, Y., Nakagawa, K., & Fukuoka, M. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.01.005 · Cited by 77
Targeted Therapy and Immunotherapy in the Treatment of Non–Small Cell Lung Cancer
Shroff, G. S., de Groot, P. M., Papadimitrakopoulou, V. A., Truong, M. T., & Carter, B. W. (2018) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2018.01.012 · Cited by 78
Self-citationNazha, B., Yang, J. C., & Owonikoko, T. K. (2020) · Future Oncology · doi:10.2217/fon-2020-0951 · Cited by 79
Caputo, V., Ciardiello, F., Corte, C. M. D., Martini, G., Troiani, T., & Napolitano, S. (2023) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2023.00125 · Cited by 80
Blakely, C. M., Urisman, A., Gubens, M. A., Mulvey, C. K., Allen, G. M., SHIBOSKI, S. C., Rotow, J. K., Chakrabarti, T., Kerr, D. L., Aredo, J. V., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00071 · Cited by 78
Jiang, X., Xu, Y., Huang, M., Zhang, L., Su, M., Chen, X., & Lu, J. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.123 · Cited by 77
Kim, M., Kizilbash, S. H., Laramy, J. K., Gampa, G., Parrish, K. E., Sarkaria, J. N., & Elmquist, W. F. (2018) · Pharmaceutical Research · doi:10.1007/s11095-018-2455-9 · Cited by 81
Lin, J. J., Schoenfeld, A. J., Zhu, V. W., Yeap, B. Y., Chin, E. N., Rooney, M. M., Plodkowski, A. J., Digumarthy, S. R., Dagogo‐Jack, I., Gainor, J. F., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.10.014 · Cited by 78
Liu, Y., Li, Y., Ou, Q., Wu, X., Wang, X., Shao, Y. W., & Ying, J. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.01.015 · Cited by 76
Canale, M., Petracci, E., Delmonte, A., Bronte, G., Chiadini, E., Ludovini, V., Dubini, A., Papi, M., Baglivo, S., Luigi, N. D., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9041047 · Cited by 76
The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea
Rugo, H. S., Palma, J. A. D., Tripathy, D., Bryce, R. P., Moran, S. E., Olek, E. A., & Bosserman, L. D. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-05102-x · Cited by 76
Huang, J., Meng, L., Yang, B. L., Sun, S., Luo, Z., & Chen, H. (2020) · Scientific Reports · doi:10.1038/s41598-020-61571-5 · Cited by 77
Udagawa, H., Hasako, S., Ohashi, A., Fujioka, R., Hakozaki, Y., Shibuya, M., Abe, N., Komori, T., Haruma, T., Terasaka, M., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0419 · Cited by 76
Tan, D. S. W., Leighl, N. B., Riely, G. J., Yang, J. C., Sequist, L. V. D., Wolf, J., Seto, T., Felip, E., Ponce-Aix, S., Jonnaert, M., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30267-x · Cited by 75
Wang, W., Xu, C., Chen, H., Jia, J., Wang, L., Feng, H., Wang, H., Song, Z., Yang, N., & Zhang, Y. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.03.006 · Cited by 75
Brain metastases: An update on the multi-disciplinary approach of clinical management
Mitchell, D. K., Kwon, J. H., Kubica, P. A., Huff, W. X., O'Regan, R. M., & Dey, M. (2021) · Neurochirurgie · doi:10.1016/j.neuchi.2021.04.001 · Cited by 79
Hayashi, H., Sugawara, S., Fukuda, Y., Fujimoto, D., Miura, S., Ota, K., Ozawa, Y., Hara, S., Tanizaki, J., Azuma, K., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3194 · Cited by 77
Yan, R., Fan, X., Xiao, Z., Liu, H., Huang, X., Liu, J., Zhang, S., Yao, J., An, G., & Ge, Y. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.01.030 · Cited by 75
Minasian, L. M., O’Mara, A. M., & Mitchell, S. A. (2022) · Patient Related Outcome Measures · doi:10.2147/prom.s256567 · Cited by 75
Understanding EGFR heterogeneity in lung cancer
Passaro, A., Malapelle, U., Re, M. D., Attili, I., Russo, A., Guerini‐Rocco, E., Fumagalli, C., Pisapia, P., Pepe, F., Luca, C. D., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000919 · Cited by 75
Liquid biopsy into the clinics: Current evidence and future perspectives
Boukovala, M. A., Westphalen, C. B., & Probst, V. (2024) · The Journal of Liquid Biopsy · doi:10.1016/j.jlb.2024.100146 · Cited by 77
Blood-based tumor biomarkers in lung cancer for detection and treatment
Mamdani, H. M., Ahmed, S. S., Armstrong, S. A., Mok, T. S. K., & Jalal, S. I. (2017) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.09.03 · Cited by 75
Self-citationSambrooks, C. L., Baro, M., Quijano, A., Narayan, A., Cui, W., Greninger, P., Egan, R. K., Patel, A. A., Benes, C. H., Saltzman, W. M., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0505 · Cited by 74
Zhu, V. W., Klempner, S. J., & Ou, S. I. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.09.008 · Cited by 73
Liu, X., Jiang, T., Li, X., Zhao, C., Li, J., Zhou, F., Zhang, L., Zhao, S., Jia, Y., Shi, J., et al. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14838 · Cited by 74
Cardiovascular Complications of Systemic Therapy in Non-Small-Cell Lung Cancer
Zaborowska-Szmit, M., Krzakowski, M. J., Kowalski, D. M., & Szmit, S. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051268 · Cited by 73
Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2–IA3 EGFR-Mutated NSCLC: ADAURA2
Tsutani, Y., Goldman, J. W., Đačić, S., Yatabe, Y., Majem, M., Huang, X., Chen, A. R., van der Gronde, T., & He, J. (2023) · Clinical Lung Cancer · doi:10.1016/j.cllc.2023.02.002 · Cited by 73
Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment
Passaro, A., Guerini‐Rocco, E., Pochesci, A., Vacirca, D., Spitaleri, G., Catania, C., Rappa, A., Barberis, M. C. P., & de Marinis, F. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.01.003 · Cited by 73
Molecular Imaging in Cancer Drug Development
Waaijer, S. J. H., Kok, I. C., Eisses, B., Schroder, C. P., Jalving, M., Brouwers, A. H., Hooge, M. N. L., & de Vries, E. G. E. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.188045 · Cited by 73
The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib
Vishwanathan, K., Dickinson, P. A., So, K., Thomas, K., Chen, Y., de Castro, J., Dingemans, A. C., Kim, H. R., Kim, J.-H., Krebs, M., et al. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13534 · Cited by 75
Self-citationNewer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used?
Le, T., & Gerber, D. E. (2019) · Cancers · doi:10.3390/cancers11030366 · Cited by 75
Kim, S. T., Banks, K. C., Lee, S., Kim, K., Park, J. O., Park, S. H., Park, Y. S., Lim, H. Y., Kang, W. K., Lanman, R. B., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.16.00059 · Cited by 72
Radiomics signature of brain metastasis: prediction of EGFR mutation status
Wang, G., Wang, B., Wang, Z., Li, W., Xiu, J., Liu, Z., & Han, M. (2021) · European Radiology · doi:10.1007/s00330-020-07614-x · Cited by 72
Heart Failure With Targeted Cancer Therapies
Hahn, V. S., Zhang, K. W., Sun, L., Narayan, V., Lenihan, D. J., & Ky, B. (2021) · Circulation Research · doi:10.1161/circresaha.121.318223 · Cited by 73
Planchard, D., Feng, P., Karaseva, N. A., Kim, S.-W., Kim, T. M., Lee, C. K., Poltoratskiy, A., Yanagitani, N., Marshall, R., Huang, X., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100271 · Cited by 72
Self-citationPeng, P., Gong, J., Zhang, Y., Zhou, S., Li, Y., Han, G., Meng, R., Chen, Y., Yang, M., Shen, Q., et al. (2023) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2023.109681 · Cited by 76
Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?
Garinet, S., Laurent‐Puig, P., Blons, H., & Oudart, J. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7060144 · Cited by 71
Yamaguchi, H., Wakuda, K., Fukuda, M., Kenmotsu, H., Mukae, H., Ito, K., Chibana, K., Inoue, K., Miura, S., Tanaka, K., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.07.026 · Cited by 71
Sun, R., Hou, Z., Zhang, Y., & Jiang, B. (2022) · Oncology Letters · doi:10.3892/ol.2022.13528 · Cited by 77
Gray, J. E., Ahn, M., Oxnard, G. R., Shepherd, F. A., Imamura, F., Cheng, Y., Okamoto, I., Cho, B. C., Lin, M., Wu, Y.-L. L. C., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3146 · Cited by 71
Self-citationImperial, R. J. L., Toor, O. M., Hussain, A., Subramanian, J., & Masood, A. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.016 · Cited by 74
Leighl, N. B., Karaseva, N. A., Nakagawa, K., Cho, B. C., Gray, J. E., Hovey, T., Walding, A., Rydén, A., & Novello, S. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.11.006 · Cited by 73
Romaniello, D., Mazzeo, L., Mancini, M., Marrocco, I., Noronha, A., Kreitman, M., Srivastava, S., Ghosh, S., Lindzen, M., Salame, T., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0450 · Cited by 70
Biswas, A. K., Han, S., Tai, Y., Ma, W., Coker, C., Quinn, S. A., Shakri, A. R., Zhong, T. J., Scholze, H., Lagos, G. G., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0910 · Cited by 70
Epidermal Growth Factor Receptor Inhibitors in Glioblastoma: Current Status and Future Possibilities
Ezzati, S., Salib, S., Balasubramaniam, M., & Aboud, O. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042316 · Cited by 71
Monica, S. L., Minari, R., Cretella, D., Flammini, L., Fumarola, C., Bonelli, M. A., Cavazzoni, A., Digiacomo, G., Galetti, M., Madeddu, D., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1240-x · Cited by 70
Liquid Biopsy to Identify Actionable Genomic Alterations
Ou, S. I., Nagasaka, M., & Zhu, V. W. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_199765 · Cited by 71
Jiang, X.-M., Xu, Y.-L., Yuan, L.-W., Zhang, L., Huang, M.-Y., Ye, Z.-H., Su, M., Chen, X.-P., Zhu, H., Ye, R. D., et al. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0457-8 · Cited by 71
Ferro, A., Marinato, G. M., Mulargiu, C., Marino, M., Pasello, G., Guarneri, V., & Bonanno, L. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104295 · Cited by 72
Tang, Z.-H., Cao, W.-X., Su, M., Chen, X., & Lu, J. (2017) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2017.02.017 · Cited by 70
Aw, D. C., Tan, E. H., Chin, T. M., Lim, H. L., Lee, H. Y., & Soo, R. A. (2017) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12687 · Cited by 69
Riedl, J. M., Fece de la Cruz, F., Lin, J. J., Parseghian, C., Kim, J. E., Matsubara, H., Barnes, H., Caughey, B., Norden, B. L., Morales-Giron, A. A., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.01.020 · Cited by 68
Molecular Residual Disease and Adjuvant Trial Design in Solid Tumors
Coakley, M. F., García-Murillas, I., & Turner, N. C. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0152 · Cited by 69
Eide, I. J. Z., Helland, Å., Ekman, S., Mellemgaard, A., Hansen, K. H., Cicėnas, S., Koivunen, J. P., Grønberg, B. H., & Brustugun, O. T. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.03.009 · Cited by 68
Hochmair, M. J., Morabito, A., Hao, D., Yang, C., Soo, R. A., Yang, J. C., Gucalp, R. A., Halmos, B., Märten, A., & Čufer, T. (2020) · Future Oncology · doi:10.2217/fon-2020-0740 · Cited by 69
Metadata
- Authors
- Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., Lee, C. K., Sebastian, M., Templeton, A., Mann, H., Marotti, M., Ghiorghiu, S., & Papadimitrakopoulou, V. A.
- Affiliations
- Army Medical University (CN)
- Emory University (US)
- Goethe University Frankfurt (DE)
- AstraZeneca (United Kingdom) (GB)
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-02-16
- Volume
- 376
- Issue
- 7
- Pages
- 629-640
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6762027
- OpenAlex
- W2560717039
- Semantic Scholar
- bd8840946a65bec6d407a96092eda55497e49a58
- Cited by
- 3,379
- References
- 25
- Citations by year
- 2026: 198 · 2025: 280 · 2024: 301 · 2023: 318 · 2022: 410 · 2021: 438 · 2020: 404 · 2019: 365 · 2018: 389 · 2017: 268
- FWCI
- 305.08
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Research Explorer (The University of Manchester) (submittedVersion, other-oa)
- Funders
- Cancer Research UK (20465)
- National Cancer Institute (P30CA016672)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- osimertinib, T790M mutation, non-small cell lung cancer, EGFR tyrosine kinase inhibitor resistance, pemetrexed, carboplatin, cisplatin, second-line therapy, progression-free survival, central nervous system metastasis, brain metastases, objective response rate, adverse events
- MeSH terms
- Pemetrexed, Acrylamides, Adult, Aged, Aged, 80 and over, Aniline Compounds, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Female, Humans, Indoles, Lung Neoplasms, Male, Middle Aged, Mutation, Piperazines, Platinum, Pyrimidines, Disease-Free Survival, Young Adult, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
